Carboplatin
- Generic Name
- Carboplatin
- Brand Names
- Paraplatin
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12N2O4Pt
- CAS Number
- 41575-94-4
- Unique Ingredient Identifier
- BG3F62OND5
- Background
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.
Carboplatin was granted FDA approval on 3 March 1989.
- Indication
Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
Gemcitabine, Carboplatin, and Bortezomib in Advanced or Recurrent Non-Small Cell Lung Cancer
- First Posted Date
- 2004-01-13
- Last Posted Date
- 2013-02-28
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 99
- Registration Number
- NCT00075751
- Locations
- 🇺🇸
Southwest Oncology Group, San Antonio, Texas, United States
Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer
- Conditions
- First Posted Date
- 2004-01-13
- Last Posted Date
- 2013-08-12
- Lead Sponsor
- Royal College of Obstetricians and Gynecologists
- Target Recruit Count
- 150
- Registration Number
- NCT00075712
- Locations
- 🇬🇧
Birmingham Women's Hospital, Edgbaston, England, United Kingdom
🇬🇧Christie Hospital, Manchester, England, United Kingdom
🇬🇧Derriford Hospital, Plymouth, England, United Kingdom
Combination Chemotherapy With or Without Sodium Thiosulfate in Preventing Low Platelet Count While Treating Patients With Malignant Brain Tumors
- First Posted Date
- 2004-01-12
- Last Posted Date
- 2022-05-03
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 48
- Registration Number
- NCT00075387
- Locations
- 🇺🇸
Cleveland Clinic Foundation, Cleveland, Ohio, United States
🇺🇸OHSU Knight Cancer Institute, Portland, Oregon, United States
🇺🇸University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, United States
Calcitriol and Carboplatin in Treating Patients With Stage IV Prostate Cancer That Has Not Responded to Hormone Therapy
- Conditions
- First Posted Date
- 2004-01-08
- Last Posted Date
- 2017-04-28
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 19
- Registration Number
- NCT00017576
- Locations
- 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States
N99-01: Combination Chemotherapy, Radiation Therapy, and Stem Cell Transplantation in Treating Patients With Neuroblastoma
- Conditions
- Locations
- 🇺🇸
Texas Children's Cancer Center, Houston, Texas, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Children's Memorial Hospital - Chicago, Chicago, Illinois, United States
Docetaxel and Carboplatin in Treating Women With Metastatic Breast Cancer
- First Posted Date
- 2003-12-23
- Last Posted Date
- 2016-12-07
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 53
- Registration Number
- NCT00005963
- Locations
- 🇺🇸
CCOP - Duluth, Duluth, Minnesota, United States
🇺🇸Siouxland Hematology-Oncology, Sioux City, Iowa, United States
🇺🇸CentraCare Clinic, Saint Cloud, Minnesota, United States
Gemcitabine and Carboplatin Followed By Docetaxel in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-12-11
- Last Posted Date
- 2010-08-16
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 17
- Registration Number
- NCT00074204
- Locations
- 🇺🇸
Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen
- First Posted Date
- 2003-12-11
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- OHSU Knight Cancer Institute
- Target Recruit Count
- 17
- Registration Number
- NCT00074165
- Locations
- 🇺🇸
Good Samaritan Hospital Cancer Treatment Center, Hatton Institute, Cincinnati, Ohio, United States
🇺🇸Knight Cancer Institute at Oregon Health and Science University, Portland, Oregon, United States
Carboplatin, Paclitaxel, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed During Surgery
- Conditions
- Interventions
- First Posted Date
- 2003-11-26
- Last Posted Date
- 2016-07-20
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 366
- Registration Number
- NCT00003387
- Locations
- 🇺🇸
University of Chicago Cancer Research Center, Chicago, Illinois, United States
🇺🇸University of Illinois at Chicago Health Sciences Center, Chicago, Illinois, United States
🇺🇸University of California San Diego Cancer Center, La Jolla, California, United States
Amifostine in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer
- First Posted Date
- 2003-11-26
- Last Posted Date
- 2014-11-21
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 243
- Registration Number
- NCT00003313
- Locations
- 🇺🇸
North Mississippi Medical Center/Cancer Center, Tupelo, Mississippi, United States
🇺🇸RMH Regional Canter Center, Harrisonburg, Virginia, United States
🇺🇸Greater Baltimore Medical Center and Cancer Center, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.